ALA 1.61% 15.3¢ arovella therapeutics limited

Ann: Anagrelide Project Update, page-45

  1. 12,997 Posts.
    lightbulb Created with Sketch. 774
    windshift: "Not before mid-2022. There is simply too much to do to see it done before then. Even that is tight (that's less than 2 years away). But I like the program and it is worth pursuing IMO. GLTA."

    windshift/others: Because it WILL take a LOT of time (as well as a LOT of money over time...) to pursue this most important project for SUDA, there will - JIMHO - no 'soon' strong re-rating in the near-term. In fact, I tend to believe that Suda is overvalued at present - but of course, I could be completely wrong, of course.
    Moreover, "things" could suddenly change, i.e. perhaps Mr. Hopper will find another project to inject into Suda resp. inject Suda into another project...

    Time will tell as usual.

    wasa
 
watchlist Created with Sketch. Add ALA (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.